Juno Therapeutics, Inc. drugs

1 result
  • breyanzi

    (Lisocabtagene Maraleucel)
    Juno Therapeutics, Inc.
    Breyanzi is a CD19-directed CAR-T cell immunotherapy for adults with relapsed or refractory large B-cell lymphoma, CLL/SLL, follicular lymphoma, mantle cell lymphoma, or marginal zone lymphoma after 2 or more prior lines of therapy. Not indicated for primary CNS lymphoma.